Login to Your Account

Gamida Cell raises $40M for pivotal trial of cord stem cell expansion therapy

By Cormac Sheridan
Staff Writer

Monday, June 19, 2017

DUBLIN – Gamida Cell Ltd. took in $40 million in a new private financing round to enable it to complete an ongoing phase III pivotal trial of its Nicord umbilical cord blood expansion technology and to support preparations for its commercialization.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription